532 related articles for article (PubMed ID: 29456538)
1. An Uncoupling of Canonical Phenotypic Markers and Functional Potency of
Lieberman NAP; DeGolier K; Haberthur K; Chinn H; Moyes KW; Bouchlaka MN; Walker KL; Capitini CM; Crane CA
Front Immunol; 2018; 9():150. PubMed ID: 29456538
[TBL] [Abstract][Full Text] [Related]
2. Membrane-bound IL-21 promotes sustained ex vivo proliferation of human natural killer cells.
Denman CJ; Senyukov VV; Somanchi SS; Phatarpekar PV; Kopp LM; Johnson JL; Singh H; Hurton L; Maiti SN; Huls MH; Champlin RE; Cooper LJ; Lee DA
PLoS One; 2012; 7(1):e30264. PubMed ID: 22279576
[TBL] [Abstract][Full Text] [Related]
3. Ex vivo expansion of natural killer cells with high cytotoxicity by K562 cells modified to co-express major histocompatibility complex class I chain-related protein A, 4-1BB ligand, and interleukin-15.
Gong W; Xiao W; Hu M; Weng X; Qian L; Pan X; Ji M
Tissue Antigens; 2010 Dec; 76(6):467-75. PubMed ID: 20670353
[TBL] [Abstract][Full Text] [Related]
4. Long-term proliferation of functional human NK cells, with conversion of CD56(dim) NK cells to a CD56 (bright) phenotype, induced by carcinoma cells co-expressing 4-1BBL and IL-12.
Dowell AC; Oldham KA; Bhatt RI; Lee SP; Searle PF
Cancer Immunol Immunother; 2012 May; 61(5):615-28. PubMed ID: 22021067
[TBL] [Abstract][Full Text] [Related]
5. Artificial feeder cells expressing ligands for killer cell immunoglobulin-like receptors and CD94/NKG2A for expansion of functional primary natural killer cells with tolerance to self.
Michen S; Frosch J; Füssel M; Schackert G; Momburg F; Temme A
Cytotherapy; 2020 Jul; 22(7):354-368. PubMed ID: 32451262
[TBL] [Abstract][Full Text] [Related]
6. Optimization of Human NK Cell Manufacturing: Fully Automated Separation, Improved Ex Vivo Expansion Using IL-21 with Autologous Feeder Cells, and Generation of Anti-CD123-CAR-Expressing Effector Cells.
Klöß S; Oberschmidt O; Morgan M; Dahlke J; Arseniev L; Huppert V; Granzin M; Gardlowski T; Matthies N; Soltenborn S; Schambach A; Koehl U
Hum Gene Ther; 2017 Oct; 28(10):897-913. PubMed ID: 28810809
[TBL] [Abstract][Full Text] [Related]
7. The Synergistic Use of IL-15 and IL-21 for the Generation of NK Cells From CD3/CD19-Depleted Grafts Improves Their
Heinze A; Grebe B; Bremm M; Huenecke S; Munir TA; Graafen L; Frueh JT; Merker M; Rettinger E; Soerensen J; Klingebiel T; Bader P; Ullrich E; Cappel C
Front Immunol; 2019; 10():2816. PubMed ID: 31849984
[TBL] [Abstract][Full Text] [Related]
8. Activating signals dominate inhibitory signals in CD137L/IL-15 activated natural killer cells.
Zhang H; Cui Y; Voong N; Sabatino M; Stroncek DF; Morisot S; Civin CI; Wayne AS; Levine BL; Mackall CL
J Immunother; 2011 Mar; 34(2):187-95. PubMed ID: 21304401
[TBL] [Abstract][Full Text] [Related]
9. Characterization of natural killer and natural killer-like T cells derived from ex vivo expanded and activated cord blood mononuclear cells: implications for adoptive cellular immunotherapy.
Ayello J; van de Ven C; Cairo E; Hochberg J; Baxi L; Satwani P; Cairo MS
Exp Hematol; 2009 Oct; 37(10):1216-29. PubMed ID: 19638292
[TBL] [Abstract][Full Text] [Related]
10. Expansion of Human NK Cells Using K562 Cells Expressing OX40 Ligand and Short Exposure to IL-21.
Kweon S; Phan MT; Chun S; Yu H; Kim J; Kim S; Lee J; Ali AK; Lee SH; Kim SK; Doh J; Cho D
Front Immunol; 2019; 10():879. PubMed ID: 31105701
[No Abstract] [Full Text] [Related]
11. Therapeutic applications: natural killer cells in the clinic.
Miller JS
Hematology Am Soc Hematol Educ Program; 2013; 2013():247-53. PubMed ID: 24319187
[TBL] [Abstract][Full Text] [Related]
12. Building a Better Defense: Expanding and Improving Natural Killer Cells for Adoptive Cell Therapy.
Maia A; Tarannum M; Lérias JR; Piccinelli S; Borrego LM; Maeurer M; Romee R; Castillo-Martin M
Cells; 2024 Mar; 13(5):. PubMed ID: 38474415
[TBL] [Abstract][Full Text] [Related]
13. Genetically re-engineered K562 cells significantly expand and functionally activate cord blood natural killer cells: Potential for adoptive cellular immunotherapy.
Ayello J; Hochberg J; Flower A; Chu Y; Baxi LV; Quish W; van de Ven C; Cairo MS
Exp Hematol; 2017 Feb; 46():38-47. PubMed ID: 27765614
[TBL] [Abstract][Full Text] [Related]
14. Clinical-grade ex vivo-expanded human natural killer cells up-regulate activating receptors and death receptor ligands and have enhanced cytolytic activity against tumor cells.
Berg M; Lundqvist A; McCoy P; Samsel L; Fan Y; Tawab A; Childs R
Cytotherapy; 2009; 11(3):341-55. PubMed ID: 19308771
[TBL] [Abstract][Full Text] [Related]
15. Immobilized MHC class I chain-related protein A synergizes with IL-15 and soluble 4-1BB ligand to expand NK cells with high cytotoxicity ex vivo.
Gong W; Xiao W; Qian L; Gong C; Hu M; Pan X; Ji M
Cell Mol Immunol; 2010 Nov; 7(6):477-84. PubMed ID: 20871627
[TBL] [Abstract][Full Text] [Related]
16. Phenotypic and functional characterisation of locally produced natural killer cells ex vivo expanded with the K562-41BBL-mbIL21 cell line.
Shman TV; Vashkevich KP; Migas AA; Matveyenka MA; Lasiukov YA; Mukhametshyna NS; Horbach KI; Aleinikova OV
Clin Exp Med; 2023 Oct; 23(6):2551-2560. PubMed ID: 36527513
[TBL] [Abstract][Full Text] [Related]
17. A New Ex Vivo Method for Effective Expansion and Activation of Human Natural Killer Cells for Anti-Tumor Immunotherapy.
Yang H; Tang R; Li J; Liu Y; Ye L; Shao D; Jin M; Huang Q; Shi J
Cell Biochem Biophys; 2015 Dec; 73(3):723-9. PubMed ID: 27259316
[TBL] [Abstract][Full Text] [Related]
18. IL-18/IL-15/IL-12 synergy induces elevated and prolonged IFN-γ production by ex vivo expanded NK cells which is not due to enhanced STAT4 activation.
Lusty E; Poznanski SM; Kwofie K; Mandur TS; Lee DA; Richards CD; Ashkar AA
Mol Immunol; 2017 Aug; 88():138-147. PubMed ID: 28644973
[TBL] [Abstract][Full Text] [Related]
19. IL-15R alpha-IgG1-Fc enhances IL-2 and IL-15 anti-tumor action through NK and CD8+ T cells proliferation and activation.
Wu Z; Xu Y
J Mol Cell Biol; 2010 Aug; 2(4):217-22. PubMed ID: 20671116
[TBL] [Abstract][Full Text] [Related]
20. Natural killer cell engineering for cellular therapy of cancer.
Shook DR; Campana D
Tissue Antigens; 2011 Dec; 78(6):409-15. PubMed ID: 22077621
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
